Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

By W. Szafrański, A. Cukier, A. Ramírez, G. Menga, R. Sansores, S. Nahabedian, S. Peterson, H. Olsson. European Respiratory Journal, 2003

913 citations recorded by the source corpus.

Subfields: Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a66300095af7d93d1cf222c9b1eead90dfc386ce

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. P. Barnes
2. P. Calverley
3. D. Parums

In Pulmonary and Respiratory Medicine

1. D. Parums
2. P. Calverley
3. P. Barnes
4. K. Rabe
5. A. Anzueto
6. Jorgen Vestbo
7. R. Rodríguez-Roisín
8. S. Hurd

Citations in the corpus

• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. (2007, background): “An inhaled glucocorticosteroid combined with a long-acting b2-agonist is more effective than the individual components (123, 125, 126, 130, 131) (Evidence A).”
• Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution (2023, neutral): “В ка! честве первой линии терапии рекомендуется комбина! ция ингаляционных ГКС/длительнодействующих β2!аго! нистов или длительнодействующих антихолинергических препаратов [195, 212, 214, 240, 244, 251, 388].”
• Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. (2008, background): “As in other longterm COPD trials (35, 36 ), many patients failed to complete the study, with significantly more withdrawing from the placebo limb.”